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therothrombosis and High-Risk Plaque
art II: Approaches by Noninvasive Computed Tomographic/
agnetic Resonance Imaging
alentin Fuster, MD, PHD, FACC,* Zahi A. Fayad, PHD, FACC,* Pedro R. Moreno, MD, FACC,*
ichael Poon, MD, FACC,*† Roberto Corti, MD, FACC,‡ Juan J. Badimon, PHD, FACC*
ew York, New York; and Zurich, Switzerland
This second part of the review on atherothrombosis highlights the diffuse nature of the
disease analyzing the feasibility and potential of the noninvasive imaging modalities,
including computed tomography (electron-beam computed and multi-detector computed
tomography) and magnetic resonance imaging for its detection and monitoring. These
imaging modalities are being established as promising tools in high-risk cardiovascular
patients for identification and/or management of coronary calcification, stenotic or obstruc-
tive disease, high-risk plaques (not necessarily stenotic), and overall burden of the disease. In
addition, such technology facilitates the understanding of the processes involved in the
development and progression of atherothrombosis responsible for coronary, cerebral, and
peripheral ischemic events. (J Am Coll Cardiol 2005;46:1209–18) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.075College of Cardiology Foundation
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(THEROTHROMBOSIS AS A SYSTEMIC DISEASE:
LINICAL IMPACT
therothrombotic cardiovascular disease is a diffuse condi-
ion involving the coronary arteries, carotid arteries, aorta
nd peripheral arteries. However, the pathobiology of the
isease and clinical consequences vary in the four regions. In
atients with atherothrombotic disease, myocardial isch-
mia or infarction causes as much as 70% of deaths (1,2).
erebrovascular disease causes approximately 10% to 17%
f deaths in these patients, and another 10% are caused by
uptured aneurysms or visceral infarctions. Peripheral arte-
ial disease may be viewed as benign because it does not
ause direct mortality. However, it is an ominous manifes-
ation of underlying disseminated atherosclerosis and,
herefore, of mortality related to coronary disease and
erebrovascular disease (1). Thus, symptomatic individuals
i.e., those presenting with claudication) have a history of
yocardial infarction or stroke in 20% to 30% of cases and
vidence of underlying coronary disease in 50% to 70% of
ases (1–5); an abnormal ankle-brachial index (0.9) with-
ut symptoms is 90% sensitive and 95% specific for
eripheral artery disease and may also indicate underlying
isseminated atherosclerosis (4,5). Most importantly, on
ong-term follow-up, patients with peripheral arterial dis-
ase, symptomatic or not, have a two- to three-fold increase
n their rate of mortality related to myocardial infarction and
troke compared with age-matched control subjects (6,7). In
From the *Zena and Michael A. Wiener Cardiovascular Institute and the
arie-Josee and Henry R. Kravis Cardiovascular Health Center, The Mount Sinai
chool of Medicine, and †Cabrini Hospital, New York, New York; and the ‡Zurich
niversity Hospital, Zurich, Switzerland.m
Manuscript received July 14, 2004; revised manuscript received December 23,
004, accepted March 4, 2005.therothrombotic disease, the rate of mortality proportion-
lly increases with the number of regions involved and
egree of distribution of the disease (4,8,9).
The concept of multi-territory atherothrombosis has been
ecently addressed by the Trans-Atlantic Inter-Society
onsensus (TASC) (10,11) by pooling the data from
vailable studies of 1,886 patients older than 62 years of age
ith symptomatic atherothrombotic disease and by the
lopidogrel versus Aspirin in Patients at Risk of Ischemic
vents (CAPRIE) trial of 20,000 patients (12). In these
wo large populations, the data showed that 3% to 8% had
ymptomatic atherosclerotic disease in all three main arterial
erritories and 23% to 32% in two (Fig. 1).
ONINVASIVE CT/MR IMAGING OF “HIGH-RISK
LAQUES” AND DISEASE “BURDEN”
ecause the composition of “high-risk plaques” varies de-
ending on the arterial region and because striking hetero-
eneity exists in the composition of human atherothrom-
otic plaques even within the same individual, reliable
oninvasive imaging modalities are needed that can detect
therothrombotic disease in various stages and regions,
haracterize the composition of the plaques, measure the
xtent of plaque “burden,” further study the mechanisms of
laque progression, assess the response to therapy, and allow
or assessment of subclinical disease (13). We will focus on
wo most promising noninvasive techniques—computed
omography (CT) and magnetic resonance imaging (MRI)
14)—since, eventually, these techniques are likely to be
ore widely used.
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oday, two different modes of CT are available. One uses
he non-mechanical movement of the X-ray source (i.e.,
lectron-beam computed tomography [EBCT]) and the
ther involves the motion of the X-ray source and table,
ombined with multiple detectors to acquire the data in
piral or helical fashion (i.e., multi-detector-row computed
omography [MDCT]) (14). Atherosclerotic coronary cal-
ifications (15,16) most frequently are found as lumps of
alcium in advanced atherosclerotic lesions (American
eart Association [AHA] plaque type Vb) but may occur as
mall deposits of calcium earlier in the course of lesion
evelopment (16). Both EBCT and MDCT are able to
ccurately quantify the coronary calcium plaque burden.
lthough EBCT has been considered the gold standard for
he assessment of calcified plaques (17,18), MDCT usually
ncludes an initial non-enhanced scan for the screening and
uantification of coronary artery calcium (CAC) followed
y CT angiography for direct visualization of coronary
tenosis.
oronary calcium scoring by EBCT and non-enhanced
DCT. Coronary calcification is a frequent phenomenon
hat does not necessarily indicate significant obstructive
isease (15) (Fig. 2). It reflects “chronic plaque burden” as it
elates to healed plaque ruptures and/or compensatory
emodeling rather than “vulnerable or high-risk lipid-rich
laques” (16,19). However, increased chronic plaque burden
s associated with increased vulnerable or high-risk plaques
igure 1. Clinical overlap between peripheral arterial disease (PAD),
oronary artery disease (coronary), and cerebrovascular disease (cerebral) in
he Trans-Atlantic Inter-Society Consensus (TASC) working group with
early 2,000 patients (left) and in the Clopidogrel versus Aspirin in
atients at Risk of Ischemia Events (CAPRIE) trial with nearly 20,000
Abbreviations and Acronyms
CAC  coronary artery calcium
CS  calcium score
CT  computed tomography
EBCT  electron-beam computed tomography
HU  Hounsfield units
MDCT  multi-detector computed tomography
MRA  magnetic resonance angiography
MRI  magnetic resonance imaging
SSFP  steady-state free precessionf
atients (right). Compiled from data in the TASC Working Group (10)
nd the CAPRIE Steering Committee (12).nd, therefore with coronary events (20). Thus, it is only
ndirectly that calcium measurements may reflect underlying
laque biology and propensity for future plaque rupture
19).
There are various methods used to determine the amount
f CAC. The standard parameter is the Agatston score
ased slice-by-slice analysis, maximum X-ray attenuation
oefficient, and the area of calcium deposit. The Agatston
core calculates the calcium burden by multiplying the area
f the calcified lesion by a weighting factor dependent on
he peak signal of the lesion (17). Individual scores are
eparately accumulated for the left main, left anterior
escending, left circumflex, and right coronary artery. The
um of these separate scores yields a total coronary score.
owever, Agatston score is susceptible to noise artifact as
ell as to scan protocol variations, primarily regarding slice
hickness parameters. A calcium volume score that interpo-
ates sections to determine the isotropic volume of the lesion
as been more recently developed (21). The most promising
pproach is to expand volumetric quantification of coronary
alcium score (CS) to absolute mass quantification using a
hantom calibration method of hydroxy apatite indepen-
ent of different scanner properties and protocol variations
22). Thus, measurements of calcium volume and calibrated
alcium mass instead of the conventional Agatston score
ield improved reproducibility and consistency.
According to the American College of Cardiology
ACC) and AHA consensus on coronary calcium (18) and
ompetence in training (23), the clinical indications that
ay be considered are the detection of coronary calcium as
surrogate marker in patients with atypical chest pain and
igure 2. Coronary calcium lesions in the left anterior coronary artery
arrow) using an electrocardiogram-gated non– contrast-enhanced
ultidetector-row computed tomography breath hold acquisition.or quantification and follow-up of the coronary calcium
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October 4, 2005:1209–18 Atherothrombosis and High-Risk Plaque: Part IIlaque load in asymptomatic patients with cardiovascular
isk factors. However, although the 34th Bethesda Confer-
nce provides an encouraging document about the diagnos-
ic and prognostic future of noninvasive imaging (24), an
utline of clear clinical indications of CAC is still consid-
red to be premature until ongoing prospective studies
rovide more definitive answers (25). Thus far, it appears
hat the presence of CAC is a sensitive marker of patients
ith significant obstructive disease but that only a signifi-
ant extent of CAC is reliable regarding specificity (18). In
ther words, patients with no or a low calcium CAC score
ave lower probabilities of developing clinical events than
hose of high scores (26–28). Nevertheless, although estab-
ished as an indicator of overall disease extent, its percentile
anking adjusted to age and gender is more powerful for
redicting coronary events (29). As a general guideline and,
ased on the CS, plaque burden interpretation has been
raded as minimal (CS 0 to 10), mild (CS 11 to 100),
oderate (CS 101 to 400), or extensive (CS 400) (30).
evertheless, a CS of 45 in a 45-year-old man, which would
epresent above the 95th percentile, would exceed the risk of
ardiac events of a 75-year-old with similar CS, who would
ank at less than the 10th percentile (29).
Whether coronary calcium is an independent and supe-
ior marker of risk to conventional (28) or emerging risk
actors (31) as a predictor for future cardiac events is not yet
ell established. In terms of risk stratification, the algo-
ithms that combine the conventional major risk factors,
uch as those of the Framingham Heart Study or Prospec-
ive Cardiovascular Munster (PROCAM) study, remain the
ost widely used methods to estimate absolute risk for
ajor coronary events (24). The AHA Prevention V Con-
erence (32) established the use of CS assessment, among
ther noninvasive tests, as a potential tool for further
tratification in selected groups of asymptomatic patients.
or example, in patients with a pretest coronary event risk
stimated between 6% and 20% in 10 years (intermediate
isk patient) a positive CS of more than 300 to 400 would
e useful in further stratification toward a high-risk status
nd assist in decisions regarding the need for preventive
herapies (Fig. 3) (33). Indeed, there is recent supporting
vidence that a promising approach to further estimate risk
esults from this combination of CS with conventional risk
actor profile (34–36). Moreover, added to a high CS and
isk factor profile, a stress test with perfusion and/or
unction can provide further diagnostic and prognostic
nformation (Table 1). The coronary calcium measurement
rom non-enhanced MDCT appears to correlate well with
BCT (37,38). Although further comparative studies are
eeded, particularly at lower CS levels (39), acquisition time
nd radiation are less with EBCT (40), but non-enhanced
DCT yields greater reproducibility (38).
Whole-body EBCT has been performed to evaluate
oronary, carotid, and aorto-iliac arteries for atherosclerotic
alcifications. Age and hypertension were the dominant risk
actors for systemic calcified atherosclerosis. Thus, in regard ro age, approximately one-third of subjects younger than 50
ears of age were free of calcified disease, whereas all
ubjects older than 70 years of age were found to have some
alcium (41). This study suggests that there are significant
orrelations and risk factor associations for calcified athero-
clerosis in different vascular beds.
For clinical purposes, the specific patient who may benefit
he most from calcium scores is the patient with an
stimated 10-year risk of 10% to 20% (two or more risk
actors) according to the most recent national cholesterol
ducation program adult treatment panel (National Choles-
erol Education Program-Adult Treatment Panel III) exec-
tive summary (42). The rationale to perform a CS in this
atient is supported by the significant increase in the actual
isk if the test is positive, and the dramatic reduction in risk
f the test is negative, as shown in Table 1 (34).
oronary non-calcified components of plaque imaging
y contrast-enhanced MDCT. Recently, it has been
hown that CT has the potential to identify non-calcified
laques in the coronary arteries in vivo (Fig. 4) (23,43,44).
arious components of atherosclerotic plaque may be dis-
inguished and characterized by contrast-enhanced MDCT,
hich holds the promise of identifying vulnerable or high-
isk plaques (45). In an ex vivo study on human coronary
rteries, it has been shown that various imaging features of
on-calcified and calcified plaques depicted with CT cor-
elate well with histopathologic stages of atherosclerosis
efined by the AHA (46). As groups, lipid-rich, fibrous and
alcified plaques display different Hounsfield units (HU),
nd could be differentiated reliably. However, the HU units
ay overlap when differentiating individual plaques. Table 2
ives an overview of the typical morphologic appearance
ith contrast-enhanced MDCT attenuation (HU), for var-
ous plaque components. Overall, for assessment of the
on-calcified (47) components of the atherosclerotic plaque,
including coronary, carotid, and aorta), the limited spatial
esolution of contrast-enhanced MDCT will need to be
mproved for better sensitivity and accuracy; in addition,
igure 3. Predicted seven-year event rates from Cox regression model for
oronary heart disease death or non-fatal myocardial infarction (MI) for
ategories of Framingham Risk Score or coronary artery calcium score
CACS). Reprinted with permission from Greenland et al. (33).adiation dose will need to be reduced (35,40).
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Atherothrombosis and High-Risk Plaque: Part II October 4, 2005:1209–18oronary artery disease visualization by contrast-enhanced
DCT. Results of a number of promising studies concern-
ng the use of contrast-enhanced MDCT for noninvasive
oronary angiography (computed tomography angiography)
ave been published. It appears that the diagnostic accuracy
s reasonable (Fig. 5), but complete assessment can be
indered by calcium deposits in the vessel wall and by
otion artifacts, particularly in patients with high heart
ates (23,48–51). In case the heart rate of a patient is
ignificantly greater than 60 beats/min, the administration
f beta-blocker medication to slow down the heart is
ommonly used. Contrast-induced nephropathy could be a
isk for some patients.
Studies with 16-slice scanners showed improved accuracy
s compared with previous reports with four-slice scanners
52–54). These studies reported sensitivity of 73% to 95%
nd specificity of 86% to 93%, for detection of obstructive
isease (Table 3). However, some of the contrast-enhanced
DCT coronary angiography studies excluded approxi-
ately 30% of coronary segments mainly because of image
egradation from cardiac motion. The image artifacts and
igure 4. Contrast-enhanced, 16 detector-row computed tomography an
ntensity projection along the course of the proximal left coronary artery sh
rtery (arrow). (B) A cross-sectional image reconstruction of the correspo
Table 1. Changes in 10-Year Risk According
Pre-test Probability of a
Coronary Event Within
10 yrs (%)
Probab
10 yrs Accord
Electron
Calcium Score >80
1.0 3.0
2.0 6.5
3.0 9.5
4.0 12.5
5.0 15.0
6.0 18.0
7.0 20.0
10.0 27.0
15.0 38.0
20.0 46.0
Pre-test probability of a coronary event within 10 years is de
coronary event were calculated on the basis of the resu
electrocardiography. Please note that a 10% probability is inc
score is 80. Reproduced with permission from Greenlandlaque. (C) Using dedicated post-processing tools, the vessel can be stretched lo
laque.he number of excluded coronary segments may be signifi-
antly reduced (to approximately 10%) by the use of
eta-blockers to minimize cardiac motion and careful pa-
ient selection, which allows the imaging of the entire
oronary tree within one breath hold. Improvements in
DCT using the 64-slice systems equipped with more and
hinner detector rows and increased rotation speed have a
otential to allow a more reliable coronary stenosis detection
ith a very short scan time (55,56).
AGNETIC RESONANCE IMAGING
ecause atherothrombotic disease affects the entire arterial
ystem, simultaneous assessment of coronary and peripheral
rteries to the distal runoff vessels has been proposed using
ontrast-enhanced whole-body magnetic resonance angiog-
aphy (MRA) (23,57). Most important, high-resolution
RI has emerged as the potential leading noninvasive in
ivo imaging modality for atherosclerotic plaque character-
zation (13,14).
aphy of the coronary arteries in a 65-year-old patient. (A) Maximum-
large non-calcified coronary artery plaque in the distal left main coronary
vessel region proves significant lumen obstruction due to the concentric
lcium Scores and Exercise Testing
ithin
o Results of
CT (%)
Probability Within
10 yrs According to
Results of Exercise
Electrocardiography
(%)
Calcium Score <80 Abnormal Normal
0.2 4.0 0.4
0.4 8.0 0.9
0.6 12.0 1.3
0.9 15.0 1.9
1.0 19.0 2.3
1.2 22.0 2.8
1.4 25.0 3.3
2.2 33.0 4.8
3.4 44.0 7.4
4.8 52.0 10.0
rom the data on coronary risk factors. Other probabilities of
electron-beam computed tomography (CT) or exercise
to 27% if a calcium score is 80 and reduced to 2.2% if the
l. (34).giogr
ows a
ndingto Ca
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October 4, 2005:1209–18 Atherothrombosis and High-Risk Plaque: Part IIhole-body contrast-enhanced MRA and coronary
RA. Magnetic resonance angiography was found to have
igh specificity and sensitivity compared with X-ray angiog-
aphy for the detection of luminal narrowing 50% (57).
oday, whole-body MRA excludes the intracranial and
oronary arteries, for which a dedicated examination is still
equired. Several coronary MRA techniques have been
roposed for the assessment of stenosis, anomalies, and
atency of bypass grafts. T2-weighted navigator-gated fat-
uppressed free-breathing gradient-echo sequences usually
able 2. Contrast at CT and MRI of Main Components of
therothrombotic Plaque
Sequence
CT (HU) MRI (SI*)
200† T1W PDW T2W TOF
ecent
thrombus
20  to   to   to  
ipid 50    
ibrous 100    to   to 
alcium 300    
Signal intensity (SI) relative to adjacent muscle. †Vessel contrast enhancement.
  hyperintense;   isointense;   hypointense. CT  computed
omography; HU  Hounsfield unit; MRI  magnetic resonance imaging; PDW 
roton density-weighted; TOF  time-of-flight; T1W  T1-weighted; T2W 
2-weighted.
igure 5. A 38-year-old man presenting with atypical chest pain. The calci
ree (A). After administration of contrast agent, using a three-dimensional v
ide branches, could be depicted with sufficient image quality, allowing rel
on-calcified atherosclerotic vessel wall changes (B, C, D). Ao  aorta; CV 
oronary artery; LCX  left circumflex coronary artery; OM  obtuse marginare used for coronary MRA (57). Navigator-gated free-
reathing steady-state free precession (SSFP) techniques
lso have been proved effective for bright-blood coronary
RA (58,59). Recently, radial SSFP sequences, spiral
SFP sequences, and other improvements to SSFP naviga-
or also have been developed for coronary MRA (60–62).
puentrup et al. (63) recently have compared Cartesian and
on-Cartesian MRA acquisition methods. Thus far, the
reening examination revealed no calcifications within the coronary arterial
-rendering reconstruction technique, all epicardial vessels, including major
xclusion of significant coronary artery lesions or the presence of extensive
able 3. Multidetector CT Angiography of the Coronary Arteries
Patients
(n)
Sensitivity
(%)
Specificity
(%)
-slice CT (segments 2.0 mm)
Nieman et al. (50) 38 81 92
Achenbach et al. (48) 64 84 96
Knez et al. (49) 44 84 97
Leber et al. (82) 98 82 98
6-slice CT (segments 2.0 mm)
Nieman et al. (52) 58 95 86
Ropers et al. (53) 78 92 93
Mollet et al. (83) 128 92 95
6-slice CT (all segments)
Kuettner et al. (54) 60 72 97
Hoffman et al. (47) 33 63 96
ive confirmatory studies of 2005 were just published (55).
CT  computed tomography.um sc
olume
iable ecardiac vein; DBs  diagonal branches; LAD  left anterior descending
l branch; PA  pulmonary artery; RCA  right coronary artery.
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Atherothrombosis and High-Risk Plaque: Part II October 4, 2005:1209–18ensitivity and specificity are quite promising (14,57,64).
verall, it is likely that in the near future, and just for
iagnostic purposes, MRA will provide complete assess-
ent of the systemic arterial tree, whereas noninvasive CT
ith intravenous injection of contrast medium may, in part,
eplace conventional diagnostic coronary angiography (14).
egional high-spatial resolution MRI for plaque char-
cterization. Magnetic resonance differentiates plaque
omponents on the basis of biophysical and biochemical
arameters, such as chemical composition, water content,
hysical state, molecular motion, or diffusion (57). Specifi-
ally, recent improvements in MR techniques (e.g., black-
lood MRI, faster imaging, and detection coils), conducive
o high-resolution and contrast imaging, have permitted the
tudy of the different plaque components using multi-
ontrast MR, generated by T1- and T2-weighted, proton-
ensity-weighted, and time-of-flight imaging (Table 2)
13,14,65,66). Moreover, MR provides imaging without
onizing radiation and can be repeated over time.
Recent developments in MR imaging sequences have
mproved the speed of acquisition, enabling rapid extended
overage of aorta and carotid arteries (67). This develop-
ent was accomplished by modifying existing double inver-
ion recovery black blood MRI. Improvements in receiver
oil design (such as 8-channel carotid array) also have
nabled high-resolution imaging of carotid arteries (68).
ulti-contrast imaging coupled with spatially enhanced
luster analysis has allowed the quantitative evaluation of
arious plaque components (69). New, targeted contrast
gents that are being developed to selectively image athero-
clerotic plaques (70) and are currently being tested in
nimal models with new methods for nulling the blood with
igure 6. In vivo black-blood magnetic resonance imaging cross-sectional
2-weighted image of a patient with a significant plaque in the right
arotid artery (arrow). The magnified image (bottom left) shows a
omplex lipid-rich plaque.ery short T1 relaxation time (71). In vivo characterization
a
af aortic arch atherosclerosis in apolipoprotein E knockout
ice transplant model has also been recently shown (72).
RI studies of carotid artery plaques. Carotid arteries’
uperficial location and relative absence of motion present
ess of a technical challenge. Some carotid plaque MR
tudies (Fig. 6) showed the imaging and characterization of
ormal and pathological arterial walls (66,73), the quanti-
cation of plaque size (74,75), and the assessment of fibrous
ap integrity (76). A strong association between fibrous cap
hinning or rupture, as determined by MR vessel wall
maging, and the history of recent transient ischemic attack
r stroke was recently demonstrated (77). The MRA dem-
nstrates the severity of stenotic lesions and their spatial
istribution, whereas the high-resolution wall characteriza-
ion technique may show the composition of the plaques.
RA and high-resolution MR imaging of the vessel wall
an be combined (14).
Using a T1-weighted method, MR-direct thrombus im-
ging sensitive to thrombus and methemoglobin, Moody et
l. (78,79) studied patients suffering acute cerebral infarction or
ransient ischemic attacks and showed that a significant
umber of them had a complicated carotid plaque ipsilateral
o the side of their cerebral event that was corroborated in
he carotid endarterectomy specimens. Interestingly, in a
ignificant minority this occurred in vessels with stenoses
50% to 70%. The occurrence of high signal material was
lso found in the contralateral side in 30% of these patients
80).
RI studies of aortic plaques. The principal challenges
ssociated with MRI of the thoracic aorta are obtaining
ufficient sensitivity for submillimeter imaging and exclusion
f artifacts caused by respiratory motion and blood flow.
horacic aorta plaque composition and size have been
ssessed using high-resolution multi-contrast images (Fig.
). Matched MRI and transesophageal echocardiography
ross-sectional aortic segments showed a strong correlation
or plaque thickness, whereas MRI was better for plaque
haracterization (81). In a recent study of asymptomatic
ubjects, the Framingham Heart Study showed by MRI that
ortic plaque prevalence and burden (i.e., plaque volume/
ortic volume) significantly increased with age and were
igure 7. In vivo black-blood magnetic resonance images of a patient with
large plaque in the aortic arch (right panel) at the level of the descending
orta (left panel). The arrows indicate plaque. The asterisk indicates the
reas of most prominent ulcerations.
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October 4, 2005:1209–18 Atherothrombosis and High-Risk Plaque: Part IIigher in the abdominal aorta than in the thoracic aorta
82). It also was found that long-term measures of risk
actors and Framingham Heart Study coronary risk score are
trongly associated with asymptomatic aortic plaques as
etected by MRI. Other approaches for the noninvasive
etection of plaque in aorta are gadolinium-enhanced three-
imensional MRA (83) or new semi-invasive procedures
ike transesophageal MRI (84). In conclusion, MR may be
powerful noninvasive imaging tool for direct noninvasive
ssessment of aortic atherosclerotic plaque thickness, extent,
nd composition and may thereby allow the serial evaluation
f progression and therapy-induced regression of athero-
clerotic plaques.
RI studies of peripheral arteries. High-resolution MRI
f the femoral and popliteal artery and the response to
alloon angioplasty have been documented (84,85). The
xtent of the plaques could be defined such that even in
ngiographically “normal” segments of vessel, lesions with
ross-sectional areas ranging from 49% to 76% of potential
umen area were identified (85). After angioplasty, plaque
ssuring and local dissection were easily identified, and
erial changes in lumen diameter, blood flow, and lesion size
ere documented.
RI studies of coronary artery plaques. The ultimate
oal is noninvasive imaging of plaque in the coronary
rteries. By using a combination of multi-contrast MRI
equences, differentiation of fibrocellular, lipid-rich, and
alcified regions of the atherosclerotic coronary plaque is
easible, as shown in an ex vivo study on human coronary
rteries correlated to histopathology (86). Our group
dapted the black blood MR method used in the human
arotid artery and aorta to the imaging of the coronary
rterial lumen and wall. The method was validated in swine
oronary lesions induced by balloon angioplasty (87). High-
esolution, black-blood MR of both normal and atheroscle-
otic human coronary arteries was performed for direct
ssessment of coronary wall thickness and the visualization
f focal atherosclerotic plaque in the wall (Fig. 8) (88). To
lleviate the need for breath holding, real-time navigator for
igure 8. In vivo magnetic resonance black-blood cross-sectional images of
f fat (arrow), (B) a concentric fibrotic lesion in the left anterior descendi
eft anterior descending; LV  left ventricle; RCA  right coronary arterespiratory gating and real-time slice-position correction has
a
oeen reported (89). Near isotropic spatial resolution black-
lood imaging may provide a quick way to image a long
egment of the coronary artery wall and may be useful for
apid coronary plaque burden measurements (90).
n vivo monitoring of therapy with MRI. It has been
hown that in vivo MRI can be used to measure the effect of
ipid-lowering therapy (statins) in asymptomatic, hypercho-
esterolemic patients with carotid and aortic atherosclerosis
74). Atherosclerotic plaques were visualized and measured
ith MRI at different time points after initiation of lipid-
owering therapy. Significant regression of atherosclerotic
esions was observed. There was a decrease in the vessel wall
rea but no change in the lumen area at 12 months. A longer
ollow-up showed a continued reduction on vessel wall area
nd even a small, but significant, increase in the arterial
umen at 24 months (Fig. 9) (75). Similar findings were
btained with atorvastatin. A case-control study demon-
trated substantially reduced carotid plaque lipid content in
atients treated for 10 years with an aggressive lipid-
owering regimen (76,91). We have just demonstrated the
eneficial effects of statins on experimental atherosclerosis
ollowed by MRI, and additional anti-atherogenic benefits
f combining a peroxisome proliferator-activated receptor-
n coronary arteries demonstrating (A) a plaque presumably with deposition
tery, and (C) an ectatic but atherosclerotic right coronary artery. LAD 
 right ventricle. Modified from Fayad et al. (88).
igure 9. T2-weighted magnetic resonance images at two different time
oints (baseline and 24 months after initiation of lipid-lowering therapy by
tatins) from the same patient. Details of the descending aorta are shown.
t 24 months after lipid-lowering, the magnetic resonance imaging showshuma
ng arthinner plaque and smaller lipid area (hypointense signal from 1 to 4
’clock) compared with baseline (arrows). Bar scale indicates 10 mm.
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RI on the in vivo monitoring of therapies can be pivotal
or the better understanding of new pharmacological agents
efore undergoing clinical trials. It also can serve as a guide
o assess the vascular wall response by individual patients to
roven beneficial therapies.
A clear distinction between imaging the coronary arteries,
hich move, and the larger arteries, which have less motion,
s important when considering CT/MRI for research or
linical purposes. Evaluation of plaque composition by
ither technique is superior in larger arteries, including
arotids and the aorta. Despite of great advances with the
oronaries, plaque characterization in the epicardial vessels
f the heart remains a challenge that requires further work
or complete clinical application.
NTEGRATION OF NONINVASIVE CT AND MRI
ogether, CT and MRI may provide unique information,
hus allowing the assessment of subclinical disease, athero-
hrombotic progression, and its response to therapy (14,57).
omputed tomography may first be used to localize suspi-
ious atherothrombotic lesions in the coronary arteries
ithin a short scan time. Magnetic resonance angiography
oes the same in the systemic arteries, but within a much
onger scan time. Magnetic resonance imaging can then
roceed with tissue characterization of the problem sites.
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